Parathyroid hormone-related peptide (PTHrP) is a regulatory protein associated with cell growth in non-osseous tissues and with osteoclast stimulation in bone. It has been implicated in the pathogenesis of bone metastases, particularly in breast carcinoma. PTHrP is widely expressed in primary prostate cancers, but there are few reports of its expression in prostatic metastases. The aim of this study was to examine the expression of PTHrP in bone metastases from patients with untreated adenocarcinoma of the prostate. Ten bone biopsies containing metastatic deposits of untreated prostatic cancer were identified. These were immunohistochemically stained for PTHrP using a murine monoclonal antibody (PTHLP[Ab1]) and the streptavidin -biotin complex technique. Intensity of staining for PTHrP was graded by two observers. In total, PTHrP expression was positive in 5/10 specimens. This was graded as moderate in four and weak in one. In those specimens with positive staining, the expression varied between cells. There was no obvious association between expression of PTHrP and tumour differentiation. PTHrP is expressed in prostatic bone metastases and may have a role in their pathogenesis and pathophysiology. However, expression is not universal.
Introduction
Improvements in diagnostic techniques and an aging population have led to a steady increase in the incidence of prostate cancer. 1 Despite increased public awareness in the UK, the majority of cases are locally advanced or metastatic at the time of diagnosis and are beyond the scope of curative therapy. 2 In such patients bone metastases are the cause of considerable morbidity and eventual mortality in this disease. The identification of specific factors associated with bone metastasis is therefore a feature which is critical to the understanding of this disease and for the formulation and development of new therapeutic modalities. It may also allow identification of those primary tumours with greater metastatic biopotential and thereby may offer improved identification of patients who might benefit from active therapy as opposed to watchful waiting.
Parathyroid hormone-related peptide (PTHrP) was initially identified as the substance responsible for the humoral hypercalcaemia of malignancy in patients with lung, breast and renal cancers. 3 The PTHrP gene encodes three forms of protein that differ by the number of amino acids, varying in length from 139 to 173 residues. In all three forms, eight of the first 13 amino acids are common to parathormone; thereafter the sequence is unique. 4 PTHrP is able to bind to the PTH receptor through the amino terminal fragment (residues 1 -34) 5 and can therefore activate both osteoclasts and osteoblasts. The carboxy-terminal (residues 107 -139) of PTHrP has also been shown to promote formation of osteoclast-like giant cells in mouse bone cell cultures containing osteoblasts. 6 The potential influence of PTHrP on bone metabolism has led to investigation of its role in bone disease and particularly the development of bone metastases. In the field of neoplasia, the study of PTHrP has aroused significant interest in breast carcinoma, a tumour with which prostate cancer has many parallels. Tissue expression of PTHrP is found in 60% of primary breast tumours 7, 8 and in up to 92% of bone deposits in that condition. 9 Furthermore, serum levels of PTHrP are significantly higher in patients with bone metastases from breast carcinoma. 10 In addition to its effects on bone, PTHrP has also been shown to act as a growth factor for a number of nonosseous tissues in vitro. 11 It is expressed by benign 12 and malignant prostate cells, with higher levels in malignant tissue and increasing expression with rising tumour grade. 13 PTHrP is secreted by all three commonly studied human malignant prostatic cell lines (PC3, DU-145 and LNCaP), with highest levels from the bone metastasis derived PC3 line. 14 Increased proliferation of PC3 and DU-145 cells can be induced by the addition of synthetic PTHrP to cell cultures, 14 suggesting that PTHrP may be a significant autocrine factor in prostate tumour growth.
To date the investigation of PTHrP in prostate cancer has been predominantly in cell cultures and primary tumours. This study has sought to describe the expression of PTHrP in untreated human prostate cancer bone metastases, and thereby to determine whether it may have a role in the biology of this disease.
Materials and methods
Metastatic deposits were identified in diagnostic skeletal biopsies taken from 10 patients with untreated prostate cancer. All specimens were fixed in formalin and embedded in paraffin. Histological evaluation for tumour grade was performed by two independent observers using haematoxylin and eosin stained sections. The prostatic origin of all bone deposits was confirmed by immunohistochemical staining for prostate specific antigen (PSA).
For immunohistochemical staining, 7 mm sections were dewaxed by incubation at 60 C for 45 min, then immersed in xylene for 25 min. The sections were then hydrated through graded alcohols to distilled water. Endogenous peroxidase activity was quenched by immersion in 3% hydrogen peroxide for 10 min. The sections were rinsed with phosphate buffered saline (PBS) and antigen retrieval undertaken by treatment with neuraminidase 0.02 U/ ml for 60 min. Slides were then incubated in 1% horse serum for 20 min to block non-specific binding sites, washed with PBS and incubated with monoclonal mouse anti-PTHrP antibody (PTHLP[Ab1]; Calbiochem, UK) at a concentration of 2 mg/ml for 60 min at room temperature. Sections were then washed with PBS and incubated with biotinylated rabbit anti-mouse IgG (Vector Laboratories) diluted 1 : 200 for 30 min at room temperature. This was followed by incubation with streptavidin -biotin complex reagent (Dako, UK) for 30 min. Development of the peroxidase reaction was accomplished using diaminobenzidine. The sections were counterstained with haematoxylin, dehydrated through graded alcohols and mounted in Pertex. Specimens of normal skin were used as positive controls, and negative controls were obtained by substitution of the primary antibody with PBS.
PTHrP expression in the metastatic prostate cells was assessed by two observers using the criteria described by Maclennan. 15 The intensity of staining was graded from 0 to þ þ þ , as shown in Table 1 .
Results
In all specimens the bone was extensively infiltrated by PSA positive tumour cells. Of the 10 metastatic deposits, three were graded as containing well-differentiated, four moderately-differentiated and three poorly-differentiated adenocarcinoma of prostatic origin. In the positive control skin sections, PTHrP was uniformly expressed by keratinocytes. No positive staining was seen in the negative control sections. In the bone metastases PTHrP expression was seen in five of the 10 specimens; staining intensity was graded as moderate in four and weak in one. PTHrP expression was negative in five cases. In those specimens with positive expression of PTHrP in the metastatic prostate tissue, staining was heterogeneous, with between 10 and 40% of cells exhibiting unequivocal staining (Figure 1 ). There was no obvious association between expression of PTHrP and tumour differentiation, Table 2 . 
Discussion
Prostate cancer has a predilection for metastasis to the bony skeleton and in particular, for areas of haemopoietic bone marrow. 16, 17 Once there, prostate cells induce disruption of bone cellular metabolism, with hyperstimulation of both osteoblasts 16, 18 and osteoclasts. 19, 20 The mechanisms by which prostate cells initially bind and grow in bone marrow and subsequently disrupt balanced bone and bone marrow function are likely to be multifactorial 21 but one substance that may be of significance is PTHrP.
The importance of PTHrP in the development of bone metastases is illustrated by animal models. In these, treatment with an anti-PTHrP antibody at the time of tail vein inoculation of highly metastatic tumour cells reduced both tumour burden and osteoclastic bone resorption. 22, 23 Furthermore, Arguello demonstrated that osteoclast activation by PTHrP, in combination with interleukin 1, is a prerequisite for the development of bone metastases. 24 Bone metastases from prostate cancer are rarely biopsied in clinical practice as the diagnosis is usually apparent from the combination of serum PSA estimation and bone scintigraphy, and confirmation of the primary tumour is relatively straightforward using transrectal ultrasound guided biopsy. The 10 cases studied here represent a rare series of men in whom the diagnosis of metastatic prostate cancer was made following histological analysis of tissue from skeletal biopsy. Consequently there are few human studies of PTHrP in prostate cancer and none addressing its importance specifically in untreated metastatic disease. In a small number of lymph node metastases high levels of PTHrP expression have been found. 25 The observed expression of PTHrP was comparable to those seen in poorly differentiated primary tumours.
This study demonstrates that PTHrP is expressed in 50% of untreated prostatic bone metastases. Expression was not uniform and only a minority (10 -40%) of cells stained unequivocally. In the small number of specimens studied there did not appear to be a relationship between PTHrP expression and grade of the metastatic tumour. Five of the 10 prostate cancer metastases were negative for PTHrP expression. These data correlate well with the findings of Iddon et al 26 where 7/14 prostatic bone metastases expressed PTHrP, although true comparison is difficult as Iddon describes neither the tumour differentiation nor their treatment status (untreated, hormone manipulated or hormone refractory). Conflicting with these results are those of Asadi 25 and Lee, 27 who showed high levels of PTHrP expression in small numbers of metastases. It may be that within the limited size of this series there is a chance of a disproportion in the number of well and moderately differentiated tumours when compared to untreated prostatic metastases in general. Indeed, in a subsequent series of prostatic bone metastases collected prospectively we have found that all specimens were of Gleason score 7 or greater. 28 If PTHrP is an important factor in the genesis of bone metastases, then its expression in only half of the metastases is paradoxical. The primary antibody used in this study recognises amino acid residues 38 -64 of PTHrP. It is possible that tumour cells may produce fragments of PTHrP containing the active N-terminal but not this sequence, and would not therefore be recognised by this technique. It is also possible that continued dedifferentiation has occurred in the metastases and that PTHrP is no longer produced, or that PTHrP may be subject to fluctuating expression in the metastatic phenotype as has been postulated for other factors such as E-cadherin. 29 Further studies are required to assess the role of PTHrP in metastatic spread and the disturbance in skeletal metabolism characteristic of prostate cancer.
This particular study has not addressed the next step in the autocrine sequence, namely the co-expression of the PTHrP receptor by bone or cancer cells. There is also a need for further study of matched primary and metastatic prostate cancer specimens from humans to investigate PTHrP expression in both the primary and metastatic sites and to determine whether there is a correlation of expression in the different anatomical locations. This combined with studies of the action of PTHrP in vitro and in animal model systems will help to establish the true role of PTHrP in this disease. Parathyroid hormone-related peptide AAG Bryden et al
